Pharmgate's parent company launches successful IPO in China

August 10, 2012 – Jinhe Biotechnology, parent of Pharmgate LLC, successfully completed an initial public offering of 27.23 million A shares of common stock at a price of 18 yuan ($2.82) per share, according to filings. The company raised 490.14 million yuan ($76.79 million) through the issuance. The shares are traded on the SME Board of the Shenzhen Stock Exchange. China Galaxy Securities served as the lead underwriter and Crowe Horwath China Certified Public Accountants LLP is the auditor.

Jinhe Biotechnology engages in the manufacture and sale of medicated feed additives, including chlortetracycline, chlortetracycline hydrochloride and salinomycin. The company currently has fermentation volume of 4,400 cubic meters, being one of the world's largest manufacturers of feed chlortetracycline with an annual production capacity of more than 40,000 tons. In 2011, the company reported operating revenues of $113 million and net profit after taxation of $12 million. The majority of the company's business comes from chlortetracycline, of which 70 percent was exported to the United States, Canada, Southeast Asia and other countries and regions. Its marketing network is spread across China.

Colin Gray, President of Pharmgate, commented, "This is a major step forward and will permit the company to proceed with its expansion and forward integration strategy."

About Pharmgate LLC

Pharmgate LLC is the majority-owned US subsidiary of Jinhe Biotechnology Co., Ltd., P. R. China, the world leader in the production of chlortetracycline feed grade, chlortetracycline hydrochloride, salinomycin and other animal health compounds. The company has marketing or supply approvals for these products in most major markets throughout the world.

Contact: Colin Gray 1 201 327 3800

BLUE BIRD LABELS

View Labels »

GLOBAL VET LINK

Visit Website »

NEWS

  • October 12, 2016 Pharmgate concludes merger with ProtaTek International, Inc.

    September 15, 2016 Pharmgate announces agreement to acquire ProtaTek International, Inc.

    January 6, 2016 - Pharmgate Joins GVL® FeedLINK® Electronic VFD System

    August 1, 2016 - Pharmgate announces new appointments.

    January 6, 2016 - Pharmgate Joins GVL® FeedLINK® Electronic VFD System

  • November 25, 2013 - Pharmgate receives regulatory approval for its chlortetracycline product, Deracin® 22% Granular, in Canada.

    August 13, 2015 - Pharmgate is pleased to announce the relocation of its headquarters from Ramsey, New Jersey to Wilmington, North Carolina.

  • March 17, 2014 - Pharmgate Animal Health announces the Canadian launch of Aivlosin® 17% Tylvalosin Medicated Premix for the treatment of porcine proliferative enteritis (PPE) associated with Lawsonia intracellularis infection in swine

    August 8, 2013 - Pharmgate acquires chlortetracycline product licenses in Latin America.

  • August 1, 2014 - ECO Animal Health and its North American marketing joint venture, Pharmgate Animal Health, announce...

    August 1, 2014 - Pharmgate Animal Health announces two Sales and Marketing appointments.

  • November 3, 2014 - Pharmgate concludes acquisition of Pennfield Animal Health

    October 16, 2014 - Pharmgate announces agreement to acquire the assets of Pennfield Animal Health.

CONTACT US

Pharmgate Animal Health LLC
1015 Ashes Drive, Suite 102
Wilmington, NC 28405
Tel: 1-800-380-6099
Fax: 910-679-8368

Pharmgate Animal Health Canada, Inc.
5204 Tenth Line, R.R. #2
Erin, Ontario N0B 1T0
Tel: 1-800-465-2450
Fax: 910-679-8368